Nama's AI scorecard currently rates Lantheus Buy (8.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is LNTH's P/E ratio?

Lantheus trades at a trailing price-to-earnings ratio of 15.8.

When does LNTH report earnings?

Lantheus's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $1.33.

What is the LNTH price target?

The median analyst price target from 8 analysts is $105.20, with a range of $102.50 – $115.00.

Is LNTH Shariah compliant?

Nama's AAOIFI-style screen reads Lantheus as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Lantheus (LNTH)

Healthcare · Drug Manufacturers Specialty Generic · NASDAQ

Lantheus (LNTH) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $6.57B, a trailing price-to-earnings ratio of 15.8 and a free-cash-flow yield of 5.1%. Over the most recent reported fiscal year, revenue grew 0.5% and free cash flow per share fell 21.5%. Nama's AI scorecard rates it Buy, 8.2 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Buy · 8.2/10

Clearly positive, short of the top band. As of Nov 7, 2026.

Momentum

Leading · +86.6% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-20.7%

How far the last close sits under the highest price of the past five years.

Market cap	$6.57B
Trailing P/E	15.8
Price / book	5.0
Price / sales	4.2
FCF yield	5.1%
Dividend yield	—
Gross margin	60.1%
Operating margin	19.4%
Net margin	17.7%
Revenue growth (YoY)	+0.5%
Revenue growth (3-yr annual)	+18.1%
EPS growth (YoY)	-10.9%
FCF/share growth (YoY)	-21.5%
Beta	-0.1
Exchange	NASDAQ
Sector	Healthcare
Industry	Drug Manufacturers Specialty Generic

LNTH earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate $1.33). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	$1.68	$1.26	+33.3%	—
Q2 2026	Aug 6, 2026	$1.55	$1.30	+19.2%	$388.18M
Q1 2026	May 7, 2026	$1.46	$1.23	+18.7%	$377.33M
Q4 2025	Feb 26, 2026	$1.67	$1.17	+42.7%	$406.79M

LNTH analyst price target

Median target $105.20 from 8 analysts, ranging $102.50 – $115.00.

Drug Manufacturers Specialty Generic peers

Ticker	Company	Market cap	P/E
TAK	Takeda Pharmaceutical	$67.16B	42.0
TEVA	Teva Pharmaceutical Industries	$49.72B	18.0
HLN	Haleon	$40.17B	21.3
ZTS	Zoetis	$32.81B	12.0
UTHR	United Therapeutics	$23.94B	21.2
VTRS	Viatris	$22.87B	7.8
NBIX	Neurocrine Biosciences	$16.66B	16.5
ELAN	Elanco Animal Health	$12.86B	24.3

Explore live LNTH data on Nama Insights →

Recent Congressional trades

Lantheus trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Feb 11, 2025
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Feb 11, 2025
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Feb 11, 2025
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Feb 11, 2025

LNTH FAQ

Is LNTH a buy?: Nama's AI scorecard currently rates Lantheus Buy (8.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is LNTH's P/E ratio?: Lantheus trades at a trailing price-to-earnings ratio of 15.8.
When does LNTH report earnings?: Lantheus's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $1.33.
What is the LNTH price target?: The median analyst price target from 8 analysts is $105.20, with a range of $102.50 – $115.00.
Is LNTH Shariah compliant?: Nama's AAOIFI-style screen reads Lantheus as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.